Advertisement

Topics

Latest "Daiichi Pharmaceutical" News Stories - Page: 4

21:37 EST 23rd January 2019 | BioPortfolio

Here are the most relevant search results for "Daiichi Pharmaceutical" found in our extensive news archives from over 250 global news sources.

More Information about Daiichi Pharmaceutical on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Daiichi Pharmaceutical for you to read. Along with our medical data and news we also list Daiichi Pharmaceutical Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Pharmaceutical Companies for you to search.

Showing "Daiichi Pharmaceutical" News Articles 76–100 of 8,700+

Relevant

Daiichi Sankyo gains European marketing rights to Esperion's bempedoic acid https://www.firstwordpharma.com/node/1615782  $ESPR

Daiichi Sankyo gains European marketing rights to Esperion's bempedoic acid https://www.firstwordpharma.com/node/1615782  $ESPR


Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Contender could offer potency without dose-limiting toxicities

#Daiichi Submits NDA in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

#Daiichi Submits NDA in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML


Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt

Daiichi Sankyo, Merck, Pfizer Enter Collaboration

To evaluate the combination of [fam-] trastuzumab deruxtecan in combination with the checkpoint inhibitor avelumab

Daiichi acquires another ADC drug through Glycotope licensing deal

Gatipotuzumab further fills out the Japanese pharma's pipeline of antibody-drug conjugates, which have seen increased investment as of late.

Let's Make a Deal: Veracyte & J&J, Vertex & Arbor, Esperion & Daiichi Sankyo and More

With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.

Probably Relevant

DJA: ‘The Walmart of pharmaceutical’

DJA aims to cover all the pharmaceutical industry’s equipment needs, sourcing machines largely from India and Japan. The company has...Read More... The post DJA: ‘The Walmart of pharmaceutical’ appeared first on Pharmaceutical Technology.

Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat

Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to...   

Trastuzumab biosimilar now available in Japan

A biosimilar of the antitumor agent trastuzumab, an anti-HER2 antibody, has been introduced in Japan by Daiichi Sankyo.  -More- 

M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter

JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment. This move makes JW Pharmaceutical the second...Read More... The post M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter appeared first on Pharmaceutical Technology.

Daiichi Sankyo Co Ltd 4568 Financial and Strategic SWOT Analysis Review [Report Updated: 17102018] Prices from USD $125

Daiichi Sankyo Co Ltd 4568 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment...

Fukushima Radiation Concentrated in Particles, Hot Spots

NewsA new report on Fukushima Daiichi’s radioactive contamination indicates that the estimates of how much radioactivity was released remain accurate, but where it is located and concentrated are a continual source of discovery.

Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017. The research utilizes Vernalis' fragment and structure-based drug discovery platform for two undisclosed oncology targets. A...

Daiichi Sankyo Co Ltd 4568 Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Medical Equipment Deals and Alliances Profile [Report Updated: 21092018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

Daiichi Sankyo Co Ltd 4568 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryDaiichi Sankyo Company Ltd Daiichi Sankyo is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, overthecounter OTC drugs, and quasidrugs. The company classified its business operations into two segments, namely, Daiichi Sankyo Group segment and Ranbaxy Group segment. The ...

FDA approves Astellas’ Xospata for FLT3-mutated acute myeloid leukemia

The drug is the second FLT3 inhibitor to win approval, after Novartis’ Rydapt in first-line disease.

Pharmaceutical Portfolio Management Reading List

Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly… The post Pharmaceutical Portfo... The post Pharmaceutical Portfolio Management Reading List appeared first on Biotechblog.

First Filing From Bluebird And Daiichi Keeping Mum: A Status Report On Accelerated Assessment In The EU

As the European Medicines Agency gets on with its fast-track review of bluebird bio's LentiGlobin gene therapy, the Pink ...

Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a...    

Which pharmaceutical companies have the most SPCs in Ireland?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical... The post Which pharmaceutical companies have the most SPCs in Ireland? appeared first on Biotechblog.

World Regulators Wrestle With Advanced Therapies

The development of advanced therapy medicinal products is dogged by a lack of regulation and guidance and differences in what...   

Daiichi Sankyo Seals Speedier Europe Review For Quizartinib

The acute myeloid leukemia drug is the lead candidate in the strong oncology pipeline the Japan-headquartered company has assembled over...   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks